Ensign Peak Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Ensign Peak Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$76.7K	Sell	3,939 -550	-12%	-$9.97K	﹤0.01%	1665
2026 Q1	$83.7K	Hold	4,489	–	–	﹤0.01%	1607
2025 Q4	$59.2K	Sell	4,489 -1,050	-19%	-$12.4K	﹤0.01%	1656
2025 Q3	$39.7K	Sell	5,539 -3,600	-39%	-$188K	﹤0.01%	1694
2025 Q2	$431K	Hold	9,139	–	–	﹤0.01%	1594
2025 Q1	$357K	Hold	9,139	–	–	﹤0.01%	1623
2024 Q4	$495K	Sell	9,139 -33,174	-78%	-$1.69M	﹤0.01%	1597
2024 Q3	$2.13M	Sell	42,313 -10,874	-20%	-$510K	﹤0.01%	916
2024 Q2	$2.34M	Hold	53,187	–	–	﹤0.01%	848
2024 Q1	$2.67M	Sell	53,187 -461	-0.9%	-$25K	﹤0.01%	818
2023 Q4	$3.24M	Buy	53,648 +44,048	+459%	+$2.27M	0.01%	739
2023 Q3	$547K	Buy	+9,600	New	+$530K	﹤0.01%	1563
2023 Q2	–	Sell	-11,575	Closed	-$248K	–	1768
2023 Q1	$248K	Buy	+11,575	New	+$195K	﹤0.01%	1730

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ensign Peak Advisors's MLTX Position: Q2 2026 in Review

Ensign Peak Advisors reduced its MoonLake Immunotherapeutics (MLTX) stake by 12% in Q2 2026, selling an estimated $9.97K and leaving 3,939 shares worth $76.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1665.

Ensign Peak Advisors first reported a position in MLTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $3.24M in Q4 2023. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Ensign Peak Advisors held 3,939 shares of MoonLake Immunotherapeutics worth $76.7K as of Q2 2026.
Ensign Peak Advisors sold 550 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $9.97K.
MoonLake Immunotherapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1665 holding.
Ensign Peak Advisors first reported a position in MoonLake Immunotherapeutics in Q1 2023 and has held it in 13 quarters since.
Ensign Peak Advisors's MoonLake Immunotherapeutics position peaked at $3.24M in Q4 2023.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.